1-3 of 3
Alexandre Iat
Close
Sort by
Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher
Journal: Blood
Blood (2023) 142 (Supplement 1): 421.
https://doi.org/10.1182/blood-2023-184848
Published: 2023
Journal Articles

Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia

Bochra Sedaki, Alexandre Iat, Michael Loschi, Sami Benachour, Edmond Chiche, Lea Ryffel, Patricia Brugel, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Berengere Dadone, Thomas Cluzeau
Journal: Blood
Blood (2022) 140 (Supplement 1): 11718–11719.
https://doi.org/10.1182/blood-2022-164608
Published: 2022
Journal Articles

Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al. , Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Alexandre Iat, Michael Loschi, Sami Benachour, Anne Calleja, Edmond Chiche, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Patricia Brugel, Lea Ryffel, Laurène Fenwarth, Alice Marceau, Elise Fournier, Berengere Dadone, Thomas Cluzeau
Journal: Blood
Blood (2022) 140 (Supplement 1): 9105–9106.
https://doi.org/10.1182/blood-2022-164583
Published: 2022